| Literature DB >> 33101914 |
Dipak Jagdishchandra Limbachiya1.
Abstract
OBJECTIVES: The context of this article is based on two main titles those being Gynecologic Oncology and Minimal invasive surgery. The aim of this study was to report the laparoscopic management of a series of cases of endometrial carcinoma managed by laparoscopic surgical staging in Indian women.Entities:
Keywords: Endometrial carcinoma; laparoscopy; staging
Year: 2020 PMID: 33101914 PMCID: PMC7545049 DOI: 10.4103/GMIT.GMIT_96_19
Source DB: PubMed Journal: Gynecol Minim Invasive Ther ISSN: 2213-3070
Patient demographics and tumor characteristics
| Parameter | Median value |
|---|---|
| Age (years) | 56 (35-77) |
| BMI (kg/m2) | 28.3 (20.1-57.9) |
| Method of diagnosis, | |
| Fractional curettage | 71 (80.6) |
| Hysteroscopic-guided endometrial biopsy | 17 (19.3) |
| FIGO staging 2009, | |
| IA | 67 (76.1) |
| IB | 10 (11.3) |
| II | 5 ( 5.6) |
| IIIA | 0 |
| IIIB | 0 |
| IIIC1 | 5 (5.6) |
| IIIC2 | 1 (1.1 ) |
| Histology, | |
| Endometroid | 82 (93.1) |
| Serous papillary | 4 (4.5) |
| Malignant mixed Mullerian tumor | 2 (2.3) |
| Grade ( | |
| 1 | 54 (65.8) |
| 2 | 14 (17.1) |
| 3 | 14 (17.1) |
| Positive peritoneal cytology in lavage, | |
| Present | 0 |
| Absent | 88 |
| Omental metastasis, | |
| Present | 0 |
| Absent | 88 |
MI: Body mass index, FIGO: International Federation of Gynecology and Obstetrics
Intra-operative details
| Parameter | Median value |
|---|---|
| Blood loss (ml) | 100 (60-160) |
| Operative time (min) | 174 (113-268) |
| Maximum tumor diameter (cm) | 3.5 (0.7-7) |
| Pelvic lymph node retrieval | |
| Right | 11 (4-26) |
| Left | 11 (3-25) |
| Para-aortic LN retrieval | 9 (3-22) |
| LVSI | |
| Present | 7 (7.9) |
| Absent | 81 (92.1) |
LVSI: Lymph-vascular space invasion, LN: Lymph node
Recurrence and treatment
| Age | Stage | Histology | Grade | LVSI | MI (%) | Lymph node metastasis | Adjuvant tx | Local recurrence | Distant recurrence | Time to recur (months) | Tx | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58 | IIIC1 | Endometroid | 3 | Present | <50 | Present | CCRT | Right port | Nil | 9 | Excision and CT | NED |
| 58 | IA | Endometroid | 3 | Present | <50 | Absent | VBT | Nil | Malignant ascites | 18 | CT | DOD |
| 56 | IIIC2 | Serous | 3 | Present | >50 | Present | CCRT | Nil | Malignant ascites | 15 | CT | DOD |
| 60 | IB | Endometroid | 3 | Absent | >50 | Absent | EBRT | Nil | Right supraclavicular LN | 8 | Excision and CT | NED |
| 62 | IB | Endometroid | 3 | Present | <50 | Absent | EBRT | Nil | Right Lung | 10 | CT | DOD |
LVSI: Lymph-vascular space invasion, MI: Myometrial invasion, LN: Lymph node, tx: Treatment, Tx: Treatment after recurrence, CCRT: Sandwich chemoradiation, CT: Systemic chemotherapy, VBT: Vaginal brachytherapy, EBRT: External beam radiotherapy, NED: No evidence of disease, DOD: Died of disease
Figure 1Overall survival curve